Trial Profile
A Prospective, Open-label, Multi-centric Study to Evaluate the Efficacy and Safety of Inj. Romiplostim of Intas Pharmaceuticals Ltd. in Adult Indian Patients with Chronic Refractory Idiopathic Thrombocytopenic Purpura. - NA
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 02 Sep 2016 New trial record